Entries |
Document | Title | Date |
20100249023 | ISOFLAVONE FORMULATION - This invention relates to the formulations of isoflavones with soluble carrier proteins, for example whey proteins. The formulations display increased lipid modulating activity without increased estrogenic activity, relative to isoflavone alone and may be useful, for example in therapeutic applications, such as the treatment of metabolic dysfunction, cancer and skin conditions. | 09-30-2010 |
20100267626 | METHODS AND COMPOSITIONS FOR MEASURING WNT ACTIVATION AND FOR TREATING WNT-RELATED CANCERS - The present application describes methods of regulating or modulating (e.g., antagonizing or inhibiting) Wnt signaling by administering Axin stabilizers. The application also describes methods of using Axin stabilizers described herein for the treatment, diagnosis, prevention, and/or amelioration of Wnt signaling-related disorders. | 10-21-2010 |
20100286034 | USES FOR AQUEOUS STREAMS CONTAINING PROTEINS - The present invention relates to a protein hydrolysate comprising free amino acids and peptides whereby the weight ratio of free amino acids to peptides is about 1:1 and wherein at least about 50 molar % of the peptides has a molecular weight of 400 Da or less. This composition may be rich in one or more branched-chain amino acid-(BCAA-) and or glutamine-containing di- or tripeptides. Also, the invention relates to the use of a water soluble protein-containing aqueous fraction obtained from a wet-milling process or the protein hydrolysate in: the manufacture of a medicament for the treatment or prevention of a condition associated with inappropriate blood sugar metabolism; aiding recovery and/or endurance during or after exercise; stimulating the generation of lean body mass; infant nutrition; or the preparation of a food or feed composition or a food or feed supplement. | 11-11-2010 |
20100311647 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance. | 12-09-2010 |
20100311648 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES - The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) | 12-09-2010 |
20100317570 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor - The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides. | 12-16-2010 |
20100317571 | METHODS FOR REDUCING CD36 EXPRESSION - The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 12-16-2010 |
20100323954 | CHIMERIC POLYPEPTIDES AND USES THEREOF - The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions. | 12-23-2010 |
20100331244 | PHARMACEUTICAL COMPOSITION, FOOD OR DRINK, AND METHODS RELATED THERETO - A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes. | 12-30-2010 |
20110015123 | Modulation of GLUT4 Gene Promoter activity BY AHNAK - Agents capable of alleviating AHNAK phosphoprotein-mediated repression of GLUT4 gene expression are useful for prevention, treatment, and/or alleviation of insulin resistance associated with obesity, lipotoxicity, hypertension, metabolic syndrome and type 2 diabetes. Preferred agents are double-stranded siRNAs. | 01-20-2011 |
20110015124 | LEPTIN AGONIST AND METHODS OF USE - Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, insulin resistance, lipodystrophy and hypothalamic amenorrhea, anorexia-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance. | 01-20-2011 |
20110021419 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders - Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described. | 01-27-2011 |
20110028389 | USE OF INFANT FORMULA WITH REDUCED PROTEIN CONTENT - A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of protein per 100 kcal. As IGF-1 is known to be a key control point in nutritional regulation of growth, this may offer a method of reducing the risk of developing obesity in later life. | 02-03-2011 |
20110028390 | Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors - The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R | 02-03-2011 |
20110034372 | TRUNCATED ACTIVIN TYPE II RECEPTOR AND METHODS OF USE - The present invention provides a substantially purified growth differentiation factor (GDF) receptor, including a GDF-8 (myostatin) receptor, as well as functional peptide portions thereof. In addition, the invention provides a virtual representation of a GDF receptor or a functional peptide portion thereof. The present invention also provides a method of modulating an effect of myostatin on a cell by contacting the cell with an agent that affects myostatin signal transduction in the cell. In addition, the invention provides a method of ameliorating the severity of a pathologic condition, which is characterized, at least in part, by an abnormal amount, development or metabolic activity of muscle or adipose tissue in a subject, by modulating myostatin signal transduction in a muscle cell or an adipose tissue cell in the subject. The invention also provides a method of modulating the growth of muscle tissue or adipose tissue in a eukaryotic organism by administering an agent that affects myostatin signal transduction to the organism. | 02-10-2011 |
20110039766 | METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME - The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 02-17-2011 |
20110046045 | Method of treating obesity and metabolic disorders related to excess adipose tissue by administration of sFRP-5 peptide - Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject. Also disclosed is a screen for molecules that can reduce the amount of adipose tissue in a subject. | 02-24-2011 |
20110046046 | PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR DIABETES OR OBESITY - Disclosed is a safe and non-toxic prophylactic or therapeutic composition for diabetes or obesity. The prophylactic or therapeutic composition for diabetes or obesity comprises as an active ingredient, a calcium receptor activator such as γ-Glu-X-Gly, wherein X represents an amino acid or an amino acid derivative; γ-Glu-Val-Y, wherein Y represents an amino acid or an amino acid derivative; γ-Glu-Ala; γ-Glu-Gly; γ-Glu-Cys; γ-Glu-Met; γ-Glu-Thr; γ-Glu-Val; γ-Glu-Orn; Asp-Gly; Cys-Gly; Cys-Met; Glu-Cys; Gly-Cys; Leu-Asp; γ-Glu-Met(O); γ-Glu-γ-Glu-Val; γ-Glu-Val-NH | 02-24-2011 |
20110065632 | PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN-DOPAMINE CONJUGATES - The present invention is directed to improvements in compositions containing a somatostatin-dopamine conjugate which retains both somatostatin and dopamine activity in vivo, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH | 03-17-2011 |
20110098216 | THERAPEUTIC USES OF COLOSTRININ - There is provided the use of Colostrinin for the treatment of obesity. | 04-28-2011 |
20110105389 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders. | 05-05-2011 |
20110124552 | GMCSF and Truncated CCL2 Conjugates and Methods and Uses Thereof - A conjugate protein comprising a GM-CSF or a fragment thereof and a truncated CCL2 is described. The conjugate protein has unexpected immune suppressive, anti-obesity and tumoricidal properties and is useful in a variety of therapeutic applications. | 05-26-2011 |
20110136732 | INFANT NUTRITIONAL COMPOSITIONS FOR PREVENTING OBESITY - The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic acid and alpha-linolenic acid. | 06-09-2011 |
20110144006 | PROTEIN COMPOSITION - The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L. The invention may be in the shape of a powder, capsules, pellets, tablets, effervescent tablets or food products comprising said protein composition. | 06-16-2011 |
20110144007 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 06-16-2011 |
20110152180 | BIOACTIVE PENTAPEPTIDES FROM RICE BRAN AND USE THEREOF - In general, the invention relates to novel bioactive pentapeptides from heat stabilized defatted rice bran having anti-cancer, anti-obesity, anti-Alzheimer and other health-promoting activities proteins. The bioactive pentapeptides can be incorporated into pharmaceutical, nutraceuticals and food compositions having at least the bioactive pentapeptide as an active ingredient. | 06-23-2011 |
20110160128 | Corin for Treating Obesity and Diabetes - Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The invention also provides a method of treating obesity in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. Further provided is a method of treating diabetes type II in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. | 06-30-2011 |
20110178005 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH OVERWEIGHT ANIMALS - The invention encompasses compositions and methods for treating disorders and diseases associated with overweight. The application also encompasses genes differentially expressed in animals and particularly to genes differentially expressed in overweight animals compared to lean animals. | 07-21-2011 |
20110183897 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 07-28-2011 |
20110195895 | FGF21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 08-11-2011 |
20110212887 | METHODS OF TREATING OBESITY USING ENTEROSTATIN - The present invention provides methods of treating or preventing disorders or conditions associated with enterostatin deficiency by administering to a subject in need thereof an effective amount of enterostatin. The present invention also provides methods of selecting a subject for therapy with enterostatin. Exemplary disorders or conditions associated with enterostatin deficiency include overweight, obesity, metabolic disorders, hypertension, lipid related disorders, and type II diabetes. | 09-01-2011 |
20110224135 | USE OF CONKUNITZIN-S1 FOR THE MODULATION OF GLUCOSE-INDUCED INSULIN SECRETION - The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions. The present invention furthermore relates to a method of screening for (poly)peptides derived from Conkunitzin-S1 suitable for specifically modulating the activity of a channel having the activity of a Kv1.7 containing channel, comprising: (a) altering the amino acid sequence of Conkunitzin-S1 represented by SEQ ID NO: 1 by deleting and/or inserting and/or replacing at least one amino acid; and (b) determining the modulatory effect of the (poly)peptide obtained in step (a) (i) on a channel having the activity of a Kv1.7 containing channel and (ii) on channels, preferably potassium channels, not having the activity of a Kv1.7 containing channel, which are optionally expressed on the same cell as the channel having the activity of a Kv1.7 containing channel. | 09-15-2011 |
20110230398 | Apolipoprotein C-II or its active fractions for the prevention or treatment of obesity and related metabolic disorders - Apoliporotein C-II or any active fraction of its amino acid sequence that activates lipoprotein lipase (LPL) in mammals. Increase in activity of LPL can increase expenditure of energy, and therefore an activator of LPL can be an effective agent for the prevention or treatment of obesity or related metabolic disorders, including cardiovascular disease, diabetes and hypertension in mammals including domestic pets and humans. Apolipoprotein C-II or its active fractions can be used as a diet supplement in the form of fortification to a natural product such as milk, cereal, beverage; as a nutritional supplement; or as a therapeutic agent in conventional forms of administration. | 09-22-2011 |
20110245158 | High Protein Supplement - The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine. | 10-06-2011 |
20110251121 | USE OF CYSTEINE-RICH WHEY DERIVED PROTEIN IN PATIENTS RECEIVING CHEMOTHERAPY AND/OR RADIOTHERAPY TO IMPROVE PATIENT SURVIVAL - A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the clinical outcome, that is, negatively affect survival and increase mortality. Indeed, use of a high-cysteine undenatured whey derived protein in the treatment of cancer patients resulted in an increase in patient survival. | 10-13-2011 |
20110257084 | EXENDIN DERIVATIVE LINKED BIOTIN, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed are exendin-3 or exendin-4 derivatives modified with biotin, a preparation method thereof and a pharmaceutical composition containing the same. More specifically, disclosed are exendin-3 or exendin-4 derivatives in which the lysine residue of exedin is modified with biotin. The disclosed exendin-3 or exendin-4 derivatives modified with biotin show biological activity similar to that of native exendin and at the same time, have increased in vivo stability and are easily absorbed through the mucosa. Thus, biotin-modified exendin-3 or exendin-4 derivatives are useful for treating diseases, which can be caused by the excessive secretion of insulin, the lowering of plasma glucose, the inhibition of gastric or intestinal motility, the inhibition of gastric or intestinal emptying or the inhibition of food intake. Particularly, the biotin-modified exendin-3 or exendin-4 derivatives are useful for the treatment of diabetes, obesity and irritable bowel syndromes. | 10-20-2011 |
20110257085 | Crystal Forms of Saxagliptin and Processes for Preparing Same - Physical crystal structures of a compound of the formula I: | 10-20-2011 |
20110257086 | METHODS FOR SYNTHESIS AND USES OF INHIBITORS OF GHRELIN O-ACYLTRANSFERASE AS POTENTIAL THERAPEUTIC AGENTS FOR OBESITY AND DIABETES - The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus. | 10-20-2011 |
20110263490 | Diagnostic Methods and Combination Therapies Involving MC4R - Methods and therapeutics are provided for treating metabolic disorders by activation of melanocortin signaling pathways. Generally, the methods and therapeutics can induce activation of melanocortin receptor signaling to increase energy expenditure and induce weight loss. In one embodiment, a method for performing a diagnostic procedure can be chosen, energy expenditure then assess in light of the diagnostic procedure and a definitive procedure(s) can be selected dependent on the outcome of the energy assessment. In another embodiment, a diagnostic procedure can be chosen to activate melanocortin receptor pathways, energy expenditure can be assessed and a definitive procedure(s) can be chosen that selectively and optimally activate melanocortin receptor pathways. | 10-27-2011 |
20110275558 | LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS - The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions. | 11-10-2011 |
20110288009 | LEPTIN AND LEPTIN ANALOG CONJUGATES AND USES THEREOF - The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a leptin, a leptin analog, or OB receptor agonist. The compounds of the invention can be used to treat any disease in which increased amounts of leptin are desired, such as metabolic diseases including obesity and diabetes. | 11-24-2011 |
20110288010 | UTILIZATION OF PEPTIDES AS ACTIVE INGREDIENTS FOR SLIMMING - A method of using proteins of the SIRT family or of polypeptide or peptide fragments of SIRT proteins as an active ingredient for slimming, alone or in combination with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical and/or dermatological composition. The invention also includes the use of the peptides for treatment of cellulite and/or used to decrease, eliminate or prevent excess fat beneath the skin. | 11-24-2011 |
20110312881 | BIFUNCTIONAL POLYPEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC AND CARDIOVASCULAR DISEASES - The present invention relates to compositions comprising combinations of biologically active proteins linked to extended recombinant polymer, methods of production of the compositions and their use in treatment of metabolic and cardiovascular diseases, disorders and conditions. | 12-22-2011 |
20120004162 | Methods of Treating an Overweight or Obese Subject - The disclosure herein generally relates to methods of treating an over eight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MctAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject. | 01-05-2012 |
20120004163 | NUTRITIONAL COMPOSITION FOR INFANTS - A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt % α-linolenic acid expressed as a percentage of total fatty acid content in each case and in amounts such that the ratio of linoleic acid:α-linolenic acid is in the range from 1 to 10. | 01-05-2012 |
20120015875 | Use Of Oxandrolone In The Treatment Of Burns And Other Wounds - The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient. | 01-19-2012 |
20120028890 | ACID CONTAINING LIPID FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: i) a non-polymeric slow-release matrix ii) at least one biocompatible, (preferably oxygen containing) organic solvent; iii) at least one peptide active agent; and iv) at least one lipid soluble acid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations. | 02-02-2012 |
20120028891 | METHODS OF PROMOTING OR MAINTAINING AN ANABOLIC STATE IN A FEMALE ANIMAL - The present invention is related to methods of promoting or maintaining an anabolic state in a female animal. The methods comprise administering a composition to the female animal, with the composition comprising between about 15% to about 25% protein (w/w) and about 5% to about 15% fat (w/w). The protein source in the composition comprises chicken eggs and further comprises a second protein source selected from the group consisting of soybean meal and lamb meat | 02-02-2012 |
20120035099 | FGF21 ANALOGUES AND DERIVATIVES - Derivatives of Fibroblast Growth Factor 21 which have improved properties for treating diabetes can be prepared by a recombinant process. | 02-09-2012 |
20120040892 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders - Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described. | 02-16-2012 |
20120046221 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 02-23-2012 |
20120071399 | SULFATION OF WNT PATHWAY PROTEINS - Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Additionally provided is a method of enhancing a Wnt signaling pathway comprising contacting an LRP5/6 receptor in the Wnt signaling pathway with either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, in a manner sufficient to enhance the Wnt signaling pathway. Further provided is a method of treating a subject having a disease exacerbated by inhibition of a Wnt signaling pathway comprising administering either of the above-described compositions that comprise a sequence of a sclerostin fragment or is capable of inhibiting sclerostin binding to an LRP, where the tyrosine or tyrosine analog is not sulfated, to the subject in a manner sufficient to reduce the inhibition of the Wnt signaling pathway. Also, a method of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner is provided. The method comprises adding the above-described composition that is capable of inhibiting binding of a protein ligand to its binding partner to the protein ligand and its binding partner in a manner sufficient to inhibit binding of the protein ligand to its binding partner. | 03-22-2012 |
20120071400 | LIPID METABOLISM-IMPROVING REAGENT - Our objective is to provide a novel lipid metabolism-improving reagent effective in preventing and treating hyperlipidemia and obesity and to provide this reagent in food, beverages, nutritional supplements, and fodders with the ability to improve lipid metabolism. The whey protein hydrolysate as the active ingredient in the lipid metabolism-improving reagent has a molecular weight distribution of 10 kDa or less, with the main peak between 200 Da to 3 kDa, average peptide chain length (APL) of 2-8, free amino acid content of 20% or less, antigenicity of 1/10,000 or less compared with that of β-lactoglobulin. | 03-22-2012 |
20120077739 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF - Methods are provided for treating obesity or causing weight loss in a mammalian subject or patient, wherein a therapeutically effective amount of an SGLT2 inhibitor alone or optionally in combination with another anti-obesity agent, is administered to a mammalian subject or patient. In addition, a pharmaceutical composition is provided which comprises an SGLT2 inhibitor, alone or in combination with another anti-obesity agent, and a pharmaceutically acceptable carrier thereof. | 03-29-2012 |
20120083442 | MYOSTATIN BINDING AGENTS - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 04-05-2012 |
20120088720 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES - Disclosed herein are compounds that selectively inhibit members of the PTP family of enzymes. Synthesized compounds demonstrated selective inhibition of TC-PTP. Also provided are methods of using the compounds and formulations containing the compounds. Also described is a fluorescence-tagged combinatorial library synthesis and screening method. And methods of using these compounds to effect enzyme activity both in cells and in vitro as well as method of using these compounds to treat diseases in human and animals. | 04-12-2012 |
20120108503 | METHODS FOR TREATING TYPE I DIABETES WITH LEPTIN AND LEPTIN AGONISTS - The present invention provides for methods of treating type I diabetes by inducing hyperleptinemia in subjects afflicted with type I diabetes. These methods can achieve normoglycemia and suppress hypergluconemia, and alleviate conditions associated with such, even in the absence of or at extremely low levels of adjunct insulin therapy, and without any appreciable increase in insulinogenesis. | 05-03-2012 |
20120122770 | Cell Cycle Arrest and Apoptosis - The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein that is necessary and sufficient for the HIV-1-induced block of cellular proliferation and induction of apoptosis. Expression of vpr in CD4.sup.+ lymphocytes results in G2 arrest, followed by apoptosis. ATR, as a cellular factor that mediates Vpr-induced cell cycle arrest, is required for activation of the Breast Cancer-Associated Protein-1 (BRCA1). In addition, the Growth Arrest and DNA Damage protein (GADD45) is upregulated by Vpr in an ATR-dependent manner. Posttranscriptional silencing of either ATR or GADD45 leads to nearly complete suppression of the pro-apoptotic and/or cell cycle arrest effect of Vpr. | 05-17-2012 |
20120122771 | STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN - The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal region of the IR α-chain, as well as the corresponding region of IGF-1R, and to methods of using the crystal and related structural information to screen for and design compounds that interact with or modulate the function of IR and/or IGF-1R. | 05-17-2012 |
20120122772 | Agent for Suppressing Elevation of Blood GIP Concentration - An agent for suppressing elevation of blood GIP concentration and an agent for preventing or improving obesity, each of which contains a polyglutamic acid as an active ingredient. | 05-17-2012 |
20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS - The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 05-24-2012 |
20120135918 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF - The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A | 05-31-2012 |
20120142585 | LEPTIN ANTAGONIST AND METHODS OF USE - This invention provides compounds that are true antagonists of the leptin receptor, in the presence and the absence of native leptin or another leptin receptor binder. These compounds may be used to inhibit leptin receptor activity, promote growth arrest or death of leptin receptor-positive cancer cells, or monitor or detect a leptin receptor-positive cell, in vitro or in vivo. These compounds may also be used to treat a weight-loss nutritional disorder, osteoporosis, rheumatoid arthritis, osteoarthritis, or inflammatory bowel disease. Also included in the invention are methods for detecting leptin receptor-positive cells, for arresting cell growth or killing cancer cells in vivo, for monitoring or detecting a leptin receptor-positive cell in vitro or in vivo, for treating a weight-loss nutritional disorder, for treating osteoporosis, for treating rheumatoid arthritis, for treating osteoarthritis, or for treating inflammatory bowel disease. | 06-07-2012 |
20120149634 | COMPOUNDS AND METHODS FOR TREATING BONE DISORDERS AND CONTROLLING WEIGHT - The present invention provides peptides and methods of their use in treating bone disorders and bone-related conditions and in treating obesity. | 06-14-2012 |
20120172293 | PEPTIDE AND USE THEREOF - The present invention aims to provide a peptide having a superior Y2 receptor agonist action and useful as an agent for the prophylaxis or treatment of obesity and the like. | 07-05-2012 |
20120178672 | Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis - A nutritional composition and method of use that improves the net balance in skeletal muscle by targeting both the synthetic and breakdown processes. The disclosed composition provides for improved protein intake to increase skeletal muscle protein accretion in stressed patients who are at risk for the development of renal insufficiency by stimulating protein synthesis. | 07-12-2012 |
20120178673 | FAT ACCUMULATION SUPPRESSOR - A fat accumulation suppressor comprising as an active ingredient a whey protein hydrolysate is provided. The hydrolysate has a molecular weight range of no higher than 10 kDa and a main peak of molecular weight at 200 Da to 3 kDa; an APL (average peptide chain length) of 2 to 8; a free amino acid content of 20% or lower; a branched chain amino acid content of 20% or higher; and an antigenicity of 1/100,000 or lower relative to β-lactoglobulin. | 07-12-2012 |
20120196795 | NOVEL EXENDIN VARIANT AND CONJUGATE THEREOF - The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight. | 08-02-2012 |
20120196796 | AMYLIN FAMILY PEPTIDES AND METHODS FOR MAKING AND USING THEM - The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk. | 08-02-2012 |
20120196797 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 08-02-2012 |
20120202739 | GDF3 ANTIBODIES AND RELATED METHODS - In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3. | 08-09-2012 |
20120208747 | NOVEL PEPTIDE FOR AUGMENTING AND EXPRESSION OF BDNF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE OR PARKINSON'S DISEASE, COMPRISING THE SAME - Disclosed are peptides for augmenting the expression of BDNF (brain-derived neurotrophic factor) and a pharmaceutical composition for the prevention and treatment of Alzheimer's disease or Parkinson's disease, comprising the same. The peptides can induce the expression of BDNF in dopamine-reactive human cells, pass easily through the blood-brain barrier thanks to their low molecular weights and are almost free of cytotoxicity. Thus, they are useful in the prevention and treatment of neuropathies such as Alzheimer's disease or Parkinson's disease. | 08-16-2012 |
20120208748 | PEPTIDE COMPOSITIONS AND METHODS FOR TREATING PATIENTS - The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome. | 08-16-2012 |
20120214734 | TREATMENT OF METABOLIC DISORDERS - The present invention provides methods for treating, preventing, and/or delaying the onset of metabolic disorders including multi-factorial syndromes such as insulin-insensitivity and metabolic syndrome by administering an effective amount of an ACE inhibitor. | 08-23-2012 |
20120214735 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS - Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. | 08-23-2012 |
20120231999 | PEPTIDIC GLP-2 AGONISTS - Novel GLP-2 analogs with improved pharmacokinetic properties are described as well as their use in the treatment of disease. | 09-13-2012 |
20120238492 | FISH PROTEIN HYDROLYSATE FOR THE USE THEREOF IN INHIBITING WEIGHT GAIN AND/OR WEIGHT LOSS - The present invention relates to fish protein hydrolysates for the use thereof in inducing weight loss and in limiting and/or inhibiting weight gain. The invention also relates to such hydrolysates in preventing and/or treating excessive weight and/or health problems linked to excessive weight. | 09-20-2012 |
20120252722 | METAL-BINDING THERAPEUTIC PEPTIDES - The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes. | 10-04-2012 |
20120264680 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 10-18-2012 |
20120283178 | LEARNING MOTIVATION IMPROVERS - The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. | 11-08-2012 |
20120289460 | Agonists of Guanylate Cyclase Useful for the Treatment of Hypercholesterolemia, Atherosclerosis, Coronary Heart Disease, Gallstone, Obesity and Other Cardiovascular Diseases - This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases. | 11-15-2012 |
20120302497 | METHODS OF TREATING MEDICAL CONDITIONS USING CALCITONIN ANALOGS - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 11-29-2012 |
20120309677 | METHODS FOR REGULATING BLOOD GLUCOSE LEVELS - The invention relates to methods and compositions for reducing blood glucose levels in hyperglycaemic subjects. The methods and compositions may therefore be suitable for treating a disease or condition associated with hyperglycaemia such as, for example, obesity (particularly diet induced obesity (DIO)), weight gain, Type II diabetes mellitus, insulin sensitivity, impaired glucose tolerance and inflammation. In some embodiments, the methods comprise administering a melanocortin-5 receptor (MC5R) agonist to one or more skeletal muscle cells of the subject. Preferred MC5R agonists are those that specifically activate MC5R and/or enhance expression of MC5R, such as the melanocortin analogue, Ac-Nle-c[Asp-Pro-D-Nal(2′)-Arg-Trp-Lys]-NH | 12-06-2012 |
20120322723 | USE OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FOR PREPARING MEDICAMENT FOR PREVENTING OR TREATING EPITHELIUM TRAUMA OF INTESTINAL MUCOSA - The invention provides a use of the interleukin-1 receptor antagonist protein for preparing a medicament for preventing or treating epithelium trauma of the intestinal mucosa, wherein the protein is selected from: (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; (b) a protein which has a sequence having at least 70% homology with the amino acid sequence in the (a) and has the effect of preventing or treating epithelium trauma of the intestinal mucosa. The invention also provides a pharmaceutical composition comprising the protein (a) or (b) as the active component. | 12-20-2012 |
20120322724 | MOLECULES FOR TARGETING COMPOUNDS TO VARIOUS SELECTED ORGANS OR TISSUES - The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells. | 12-20-2012 |
20120322725 | GLUCAGON ANTAGONIST-GIP AGONIST CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY - Provided herein are peptide combinations comprising a GIP agonist peptide and a glucagon antagonist peptide. In some embodiments, the peptide combination is provided as a composition, e.g., a pharmaceutical composition, while in other embodiments, the peptide combination is provided as a kit. In yet other embodiments, the peptide combination is provided as a conjugate, e.g., a fusion peptide, a heterodimer. In specific aspects, the GIP agonist peptide is an analog of native human glucagon. In specific aspects, the glucagon antagonist peptide is an analog of native human glucagon. In some embodiments, the GIP agonist peptide is covalently attached to the glucagon antagonist peptide via a linker. Methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the peptide compositions described herein are further provided. | 12-20-2012 |
20120322726 | THERAPEUTIC AGENT FOR EATING DISORDERS - Disclosed is a highly safe and effective therapeutic agent for eating disorders, which contains, as an active ingredient, a water-soluble fraction of a hydrolysis product of casein. The hydrolysis product is obtained by means of pepsin. | 12-20-2012 |
20130065820 | SYNTHETIC MYOSTATIN PEPTIDE ANTAGONISTS - The present invention relates to novel synthetic myostatin antagonists, comprising a synthetic mature myostatin peptide, wherein the peptide comprises at least two cysteine residues at positions | 03-14-2013 |
20130065821 | COMPOSITION FOR PREVENTING AND IMPROVING METABOLIC SYNDROME - A method for improving blood HDL/LDL cholesterol ratio, reducing blood triglyceride level, reducing blood sugar level, and/or reducing body weight, that includes ingesting a composition containing a concentrated soybean germ product. The soybean germ product includes soybean germ protein; 1.0% by weight or less of saponin relative to the total weight of the soybean germ product; and 0.5% by weight or less of isoflavone relative to the total weight of the soybean germ product. | 03-14-2013 |
20130072425 | SAPOSIN-A DERIVED PEPTIDES AND USES THEREOF - The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50 | 03-21-2013 |
20130072426 | DIAGNOSTIC METHODS FOR OBESITY AND RELATED DISORDERS - Methods for detecting the presence of auto-antibodies to antigens expressed by adipose tissue are provided. Also provided are methods for diagnosing, prognosing and treating obesity and/or metabolic syndrome. | 03-21-2013 |
20130079276 | LOW PROTEIN INFANT FORMULA WITH INCREASED ESSENTIAL AMINO ACIDS - The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula. | 03-28-2013 |
20130085098 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants. | 04-04-2013 |
20130116171 | METHODS FOR TREATING METABOLIC DISORDERS USING FGF - The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. | 05-09-2013 |
20130143796 | CHIMERIC POLYPEPTIDES AND USES THEREOF - The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions. | 06-06-2013 |
20130143797 | Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof - The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α | 06-06-2013 |
20130165369 | METHOD OF TREATING OBESITY AND METABOLIC DISORDERS RELATED TO EXCESS ADIPOSE TISSUE BY ADMINISTRATION OF sFRP-- PEPTIDE - Disclosed is a method of reducing the amount of adipose tissue in a subject comprising administering to the subject an amount of an sFRP-5 peptide effective to reduce the amount of adipose tissue, or an amount of a molecule effective to stimulate expression of the sFRP-5 peptide in the subject. Also disclosed is a screen for molecules that can reduce the amount of adipose tissue in a subject. | 06-27-2013 |
20130165370 | Counteracting Drug-Induced Obesity Using GLP-1 Agonists - The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug. | 06-27-2013 |
20130172242 | GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders. | 07-04-2013 |
20130190230 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS - A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically effective amount of amylin, an amylin agonist, or an amylin derivative to treat the cognitive impairment or deficit. | 07-25-2013 |
20130190231 | PEPTIDE FOR SUPPRESSING AND TREATING OBESITY - The present invention relates to a composition for preventing, alleviating or treating obesity comprising a partial fragment of HIV-1 (Human Immunodeficiency Virus-1) Tat (Trans activator of transcription) protein. The peptides of the present invention induce anorexia and increase lipolysis, β-oxidation of free fatty acids, thermogenesis, and total energy expenditure, therefore may be effectively used for preventing or treating diseases related to metabolic imbalance such as obesity. | 07-25-2013 |
20130190232 | N-TERMINAL MODIFIED FGF21 COMPOUNDS - Analogues of FGF21 carrying a modifying, substituted ethylene or benzyl group can be used for treatment or prevention of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). | 07-25-2013 |
20130196904 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES - The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes | 08-01-2013 |
20130196905 | USE OF GLYCOMACROPEPTIDE TO IMPROVE WOMEN'S HEALTH - Methods for improving the health of a female human or non-human animal are disclosed. The methods include the step of administering to the animal compositions including an effective amount of glycomacropeptide (GMP) for effectuating the methods. Specifically, the methods can be used to increase the rate of fat metabolism or fat oxidation, decrease percentage of body fat, increase the rate of bone mineralization, increase bone mineral content, increase bone mineral density, and/or increase bone strength in the animal. | 08-01-2013 |
20130203658 | Low-Caloric High-Protein Nutritional Composition for the Stimulation of Muscle Protein Synthesis - The present invention relates to the use of a low-caloric high-protein nutritional composition for use in the prevention or treatment of a disease or condition in a mammal, which involves muscle decline, as well as to specific low-caloric high-protein nutritional compositions for stimulating muscle protein synthesis in a mammal. In particular, the invention relates to the use of a nutritional composition comprising per 100 kcal: (i) at least about 12 g of proteinaceous matter which comprises at least about 80 weight % of whey protein, relative to the total proteinaceous matter, and which comprises at least about 11 weight % of leucine, relative to the total proteinaceous matter, of which at least about 20 weight % is in a free form, relative to the total leucine, (ii) a source of fat and a source of digestible carbohydrates, for the prevention or treatment of a disease or condition which involves muscle decline in a mammal, especially an elderly mammal, wherein the nutritional composition is administered as 1 to 2 servings daily, each serving comprising between 80 and 200 kcal. | 08-08-2013 |
20130210713 | COLLAGEN POWDER - The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the invention is suitable as a food additive in food products for the reduction of hunger and as a possible treatment of obesity and its pathophysiological consequences, such as metabolic syndrome. | 08-15-2013 |
20130225484 | STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 08-29-2013 |
20130231277 | CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS - The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention. | 09-05-2013 |
20130237476 | ADIPOSE TISSUE TARGETED PEPTIDES - The application provides synthetic peptide conjugates capable of targeting and causing ablation of adipose tissue in mammal comprising at least one targeting peptide and at least one therapeutic peptide. The synthetic peptide conjugates are envisaged to have decreased physiological toxicity and/or enhanced in situ cytotoxicity compared to the peptide CKGGRAKDC-GG- | 09-12-2013 |
20130244931 | Novel GLP-1 Derivatives - Novel polypeptide derivatives having protracted profile of action. | 09-19-2013 |
20130252884 | FGF21 ANALOGUES AND DERIVATIVES - Novel analogues of Fibroblast Growth Factor 21 (FGF21), derivatives thereof having a modifying moiety covalently attached thereto, and pharmaceutical use of these analogues and derivatives, in particular, for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD) are described. | 09-26-2013 |
20130274181 | OBESITY-RELATED GENES AND THEIR PROTEINS AND USES THEREOF - The invention provides for methods of treating obesity or an obesity-associated disorder. | 10-17-2013 |
20130281363 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 10-24-2013 |
20130310310 | SITE-DIRECTED PEG-MODIFIED EXENDIN-4 ANALOGS AND USES THEREOF - Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aa | 11-21-2013 |
20130310311 | NOVEL SELECTIVE INHIBITORS OF PROLYLCARBOXYPEPTIDASE - The present invention relates to compounds of the formulae: | 11-21-2013 |
20130324460 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants. | 12-05-2013 |
20130338063 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 12-19-2013 |
20130345122 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE NEUROTRANSMISSION - The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling. | 12-26-2013 |
20140011737 | COMPOSITIONS AND METHODS FOR REGULATING METABOLISM - The present invention features compositions and methods for treating and preventing a metabolic syndrome featuring the collagen triple helix repeat containing-1 (Cthrc1) protein. | 01-09-2014 |
20140038886 | HYDROPHOBIC MODIFIED PEPTIDES AND THEIR USE FOR LIVER SPECIFIC TARGETING - The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders. | 02-06-2014 |
20140038887 | GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR, OBESITY, AND OBESITY-RELATED DISEASES AND CONDITIONS - The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof. | 02-06-2014 |
20140057837 | METHODS AND COMPOSITIONS FOR THE "BROWNING" OF WHITE FAT - Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become brown adipose tissue in a subject include the administration of one or more agents. The agent can increase or induce hypothalamic expression of BDNF, can be a TrkB receptor agonist or a beta-3 adrenergic receptor agonist, or encode an agonist that modulates a hypothalamic-adipocyte axis. | 02-27-2014 |
20140066367 | SUBCUTANEOUS DELIVERY OF A LONG-ACTING NATRIURETIC PEPTIDE - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided. | 03-06-2014 |
20140066368 | Methods For Affecting Body Composition - Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased. | 03-06-2014 |
20140073561 | METHODS OF TREATING MEDICAL CONDITIONS USING PEPTIDES - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 03-13-2014 |
20140073562 | NASAL DELIVERY - A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders. | 03-13-2014 |
20140080756 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES - The present invention provides a compound of Formula (I) | 03-20-2014 |
20140107018 | ANTICANCER AND ANTI-OBESITY CYCLIC PEPTIDE AGENTS - A compound having formula (I) or formula (II): | 04-17-2014 |
20140107019 | ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION - Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system. | 04-17-2014 |
20140107020 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 04-17-2014 |
20140128318 | NOVEL OXYNTOMODULIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY COMPRISING THE SAME - The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy. | 05-08-2014 |
20140148382 | PEPTIDE COMPOSITIONS AND METHODS FOR TREATING PATIENTS - The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome. | 05-29-2014 |
20140171361 | METHODS FOR TREATING METABOLIC DISORDERS USING FGF - The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. | 06-19-2014 |
20140187479 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM - Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism. | 07-03-2014 |
20140187480 | METABOLIC IMPRINTING EFFECTS OF SPECIFICALLY DESIGNED LIPID COMPONENT - The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life. | 07-03-2014 |
20140194352 | Compositions and Methods for Treatment of Metabolic Disorders and Diseases - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders. | 07-10-2014 |
20140213510 | USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME - The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome. | 07-31-2014 |
20140213511 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 07-31-2014 |
20140213512 | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 - Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease | 07-31-2014 |
20140221278 | DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDES OR THEIR INHIBITORS - Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease. | 08-07-2014 |
20140221279 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING A PROLIFERATION-INDUCING LIGAND (APRIL) OR APRIL SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 08-07-2014 |
20140235534 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF - The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α | 08-21-2014 |
20140243258 | METHODS AND COMPOSITIONS FOR TARGETING ADIPOSE CELLS IN MAMMALS - Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo. | 08-28-2014 |
20140243259 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF - The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α | 08-28-2014 |
20140249075 | METHODS FOR REDUCING CD36 EXPRESSION - The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 09-04-2014 |
20140249076 | AMYLIN-CALCITONIN CHIMERIC PEPTIDES CONJUGATED TO DURATION ENHANCING MOIETIES - Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis. | 09-04-2014 |
20140256620 | METHODS FOR REDUCING CD36 EXPRESSION - The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 09-11-2014 |
20140296139 | MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL - MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein. | 10-02-2014 |
20140315795 | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types - The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes. | 10-23-2014 |
20140315796 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities. | 10-23-2014 |
20150031604 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE - The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): | 01-29-2015 |
20150031605 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF - The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A | 01-29-2015 |
20150065419 | METHODS FOR TREATING METABOLIC DISORDERS USING FGF - The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. | 03-05-2015 |
20150080294 | METHODS FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN - The invention provides methods for treating obesity in a subject comprising administering an effective amount of catestatin (CST) or its equivalent to a subject afflicted with obesity so as to maintain an effective amount of circulating catestatin in the subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue, thereby, reducing adipose tissue weight and hence treating obesity in the afflicted subject. | 03-19-2015 |
20150087585 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS - Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H-imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein. | 03-26-2015 |
20150094257 | USE OF NUTRITIONAL COMPOSITIONS FOR PREVENTING DISORDERS - The present invention relates to a method for preventing and/or treating visceral adiposity and/or to alter body fat distribution by administering a certain nutritional composition to a human subject with the age between 0 and 48 months, and preventing the occurrence of diseases later in life. | 04-02-2015 |
20150099695 | C1q/TNF-RELATED PROTEIN-9 (CTRP9) AND USE IN PREVENTION AND TREATMENT OF METABOLIC DISORDERS - Compositions and methods for treatment of obesity and/or Type II diabetes and related metabolic disorders are provided wherein the methods and treatments comprise an effective amount of an isolated and/or purified C1q/TNF-related Protein-9 (CTRP9) or a functional portion thereof, and a pharmaceutically acceptable carrier. Methods of screening for molecules which elevate levels of CTRP9 in vivo are also provided. The present inventors provide the first in vivo evidence linking CTRP9 to regulation of fat metabolism in liver and skeletal muscle via AMPK signaling pathway, and highlight its protective metabolic function in the context of HFD-mediated metabolic insults. | 04-09-2015 |
20150126438 | Novel ChREBP Isoforms and Methods Using the Same - The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP β. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP β and methods of identifying one or more agents that modulate the expression of a ChREBP β target gene. | 05-07-2015 |
20150141327 | FIBROBLAST GROWTH FACTOR 21 VARIANTS - This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants. | 05-21-2015 |
20150291677 | COMPOSITIONS AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES - The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders. | 10-15-2015 |
20150297669 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES - The present invention refers to a pharmaceutical composition that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes. | 10-22-2015 |
20150307575 | METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) - Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. | 10-29-2015 |
20150320871 | Glucagon Superfamily Peptides Exhibiting Nuclear Hormone Receptor Activity - Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 11-12-2015 |
20150361146 | MG53 Mutant, Methods of Mutation and Use Thereof - Disclosed in the present invention is a MG53 mutant, wherein any one or two or more of 7 cysteines in the RING domain at the N-terminal of MG53 are mutated into mutations of non-polar amino acids. The MG53 mutant has preventive/therapeutic effects and uses in the protection of the heart, and the treatment of heart diseases caused by cell death, while avoiding the side effects caused by MG53 such as insulin resistance, obesity, and diabetes etc. | 12-17-2015 |
20150366934 | Use of Melanocortins to Treat Insulin Sensitivity - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance. | 12-24-2015 |
20160000861 | Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3 - The invention relates to methods of treating a metabolic disorder in a subject, the method comprising administering fibroblast growth factor binding protein 3 (FGFBP3) or a variant thereof to a subject in need of treatment of a metabolic disorder. | 01-07-2016 |
20160000872 | EXERCISE-REGULATED ADIPOKINES AS THERAPY FOR DIABETES MANAGEMENT - The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject. | 01-07-2016 |
20160002303 | FUNCTIONAL PEPTIDES FOR OBESITY DISORDERS - The present invention concerns certain peptides obtainable by hydrolysis from soy glycinin by the action of supernatant cultures of strains belonging to the genera | 01-07-2016 |
20160007632 | METHOD OF USE OF ACTIVATED FUNCTIONAL PROTEINS TO IMPROVE ANIMAL HEALTH | 01-14-2016 |
20160017001 | PEPTIDE COMPOSITIONS - The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): | 01-21-2016 |
20160022764 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex. | 01-28-2016 |
20160031955 | Methods for Treating Mitochondrial Disorders and Neurodegenerative Disorders - The present invention relates to a recombinant inner mitochondrial membrane polypeptide, and its use in methods for treating mitochondrial disorders. | 02-04-2016 |
20160031960 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 02-04-2016 |
20160039897 | COMPOUNDS AND METHODS FOR TREATING OBESITY AND CONTROLLING WEIGHT - The present invention provides peptides and peptide compositions and methods of their controlling body weight and treating obesity. | 02-11-2016 |
20160046684 | Methods and compositions for treatment of PTP1B-related diseases - Cancer, obesity, and diabetes are examples of PTP1B-related diseases. The invention herein provides embodiments of therapeutic methods and compositions for treating PTP1B related diseases by engineering peptides that bind to the functional spine of PTP1B to alter the conformation of the protein and inhibit a function of PTP1B. Molecules bind to amino acid residues of the functional spine of PTP1B, regulate the catalytic cycle, and treat PTP1B-related diseases. For example, molecules bind to at least one of Tyr152, Tyr153, His175, Thr178, Pro185, Phe191, Leu192, Asn193, Cys215, Gly218, Phe280, Val287, Trp291, Lys292, Leu294, Ser295, and Glu297 to reduce at least one symptom of a PTP1B related disease. | 02-18-2016 |
20160051620 | Methods for regulating transcription of multiple genes and expression of multiple targets - This invention discloses methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide, wherein the polypeptide comprising the amino acid sequence of SEQ ID No.1 and/or homology thereof. The present polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes. | 02-25-2016 |
20160074477 | METHODS AND COMPOSITIONS FOR REJUVENATING SKELETAL MUSCLE STEM CELLS - Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed. | 03-17-2016 |
20160108087 | THERAPEUTICS FOR THE INDUCTION OF ENDOGENOUS STEROIDOGENESIS AND METHODS ASSOCIATED WITH THEIR IDENTIFICATION - The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism. | 04-21-2016 |
20160115213 | Modified FGF-21 Polypeptides and Uses Thereof - Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner. | 04-28-2016 |
20160129082 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS - Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided. | 05-12-2016 |
20160129083 | MIC-1 FUSION PROTEINS AND USES THEREOF - The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds. | 05-12-2016 |
20160144006 | Maspin, Maspin Derivatives, and Maspin Mimetics for Reducing ROS, Inflammation, and Skin Aging - The present invention provides compositions, methods, and systems for treating inflammatory conditions (e.g., by inhibiting reactive oxygen species) in or on a subject with maspin, maspin derivatives, or maspin mimetics. In some embodiments, such agents are applied to the skin of a subject (e.g., to reduce skin aging). | 05-26-2016 |
20160175411 | INFANT NUTRITION WITH PROTEASE INHIBITOR | 06-23-2016 |
20160176922 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | 06-23-2016 |
20160185818 | BIDENTATE-BINDING MODULATORS OF LRRK2 AND JNK KINASES - Both JNK and LRRK2 are associated with Parkinson's disease (PD), myocardial infarction (MI), and other medical disorders. Here we report a reasonably selective and potent kinase inhibitors (e.g., compounds 6 and 10) that bound to both JNK and LRRK2 (a dual inhibitor). A bidentate-binding strategy that simultaneously utilized the ATP hinge binding and a unique protein surface site outside of the ATP pocket was applied to the design and identification of this kind of inhibitor. Compound 6 was a potent JNK3 and modest LRRK2 dual inhibitor with an enzyme IC50 value of 12 nM and 99 nM (LRRK2-G2019S), respectively. 6 also exhibited good cell potency, inhibited LRRK2:G2019S induced mitochondrial dysfunction in SHSY5Y cells, and was demonstrated to be reasonably selective against a panel of 116 kinases from representative kinase families. | 06-30-2016 |
20160199435 | METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME | 07-14-2016 |
20160200787 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS | 07-14-2016 |
20160200788 | COMPOSITIONS, USES AND METHODS FOR TREATMENT OF METABOLIC DISORDERS AND DISEASES | 07-14-2016 |
20160250281 | Peptide for Suppressing and Treating Obesity | 09-01-2016 |
20160252497 | CANCER MODELS AND ASSOCIATED METHODS | 09-01-2016 |
20190142898 | Peptides Of Syndecan-1 For Inhibiting Angiogenesis | 05-16-2019 |